Intranasal triamcinolone use during pregnancy and the risk of adverse pregnancy outcomes

J Allergy Clin Immunol. 2016 Jul;138(1):97-104.e7. doi: 10.1016/j.jaci.2016.01.021. Epub 2016 Apr 1.

Abstract

Background: Intranasal corticosteroid use during pregnancy has increased over the past decade.

Objective: We aim to estimate the safety of intranasal triamcinolone use during pregnancy, which was introduced for over-the-counter use in October 2013.

Methods: We designed a population-based prospective cohort study. From a cohort of 289,723 pregnancies in Montreal, Quebec, Canada, from 1998-2008, intranasal triamcinolone-exposed, other intranasal corticosteroid-exposed, and nonexposed women during the first trimester were studied for major congenital malformations (overall and organ specific) and spontaneous abortions and during the second/third trimesters for small-for-gestational age (SGA) newborns. The first trimester is the time window of interest for malformations and spontaneous abortion (organogenesis), and the second/third trimesters are the time windows of interest for SGA (fetal growth). Logistic regression model-based generalized estimating equations were used.

Results: Adjusting for potential confounders, use of intranasal triamcinolone during the first trimester of pregnancy was not significantly associated with the risk of overall congenital malformations (odds ratio [OR], 0.88; 95% CI, 0.60-1.28; 31 exposed cases) compared with nonexposure; however, it was associated with the risk of respiratory defects (OR, 2.71; 95% CI, 1.11-6.64; 5 exposed cases). Pregnancy exposure to intranasal triamcinolone was not significantly associated with the risk of spontaneous abortion (OR, 1.04; 95% CI, 0.76-1.43; 50 exposed cases). No association was found between second- or third-trimester exposure to intranasal triamcinolone and the risk of SGA (OR, 1.06; 95% CI, 0.79-1.43; 50 exposed cases).

Conclusions: Maternal exposure to intranasal triamcinolone during pregnancy was not associated with the risk of SGA/spontaneous abortions/overall malformations. However, it has been shown to increase the risk of respiratory system defects. Chance finding cannot be ruled out.

Keywords: Triamcinolone; major congenital malformations; pregnancy; rhinitis; small for gestational age; spontaneous abortions.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abortion, Spontaneous / epidemiology
  • Abortion, Spontaneous / etiology
  • Administration, Intranasal
  • Adult
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / adverse effects*
  • Canada / epidemiology
  • Comorbidity
  • Congenital Abnormalities / epidemiology
  • Congenital Abnormalities / etiology
  • Female
  • Glucocorticoids / administration & dosage
  • Glucocorticoids / adverse effects*
  • Humans
  • Infant, Small for Gestational Age
  • Longitudinal Studies
  • Maternal Exposure / adverse effects*
  • Odds Ratio
  • Pregnancy
  • Pregnancy Outcome*
  • Public Health Surveillance*
  • Risk Factors
  • Triamcinolone / administration & dosage
  • Triamcinolone / adverse effects*
  • Young Adult

Substances

  • Anti-Inflammatory Agents
  • Glucocorticoids
  • Triamcinolone